Iovance Biotherapeutics, Inc. IOVA Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s total liabilities & equity?
- Iovance Biotherapeutics, Inc. (IOVA) reported total liabilities & equity of $925.67M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s total liabilities & equity changed year-over-year?
- Iovance Biotherapeutics, Inc.'s total liabilities & equity decreased by 4.2% year-over-year, from $966.74M to $925.67M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s total liabilities & equity has grown at a 3.5% compound annual growth rate (CAGR), from $768.46M to $913.17M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.